BRIEF-Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration With Bristol-Myers Squibb

* FIVE PRIME THERAPEUTICS EARNS IND MILESTONE PAYMENT UNDER IMMUNE CHECKPOINT PATHWAYS DISCOVERY COLLABORATION WITH BRISTOL-MYERS SQUIBB AND ANNOUNCES THAT BMS HAS EXTENDED THE RESEARCH TERM OF THIS COLLABORATION FOR A SECOND TIME